ClinicalTrials.gg
Not yet recruitingNCT06293729Updated Apr 17, 2024

Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients

An Early Phase 1 interventional study of NGGT006 in Refractory Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Suzhou Municipal Hospital. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Suzhou Municipal Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in patients with refractory Hypercholesterolemia diagnosed by gene testing for familial hypercholesterolemia. NGGT006 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoting the clearance of low-density lipoprotein cholesterol (LDL-C).

Read the detailed description

Familial Hypercholesterolemia caused by common genetic mutations can be divided into heterozygous hypercholesterolemia (HeFH, Heterozygous Familial Hypercholesterolemia) and homozygous hypercholesterolemia (HoFH, Homozygous Familial Hypercholesterolemia). Refractory hypercholesterolemia was defined as an LDL-C level of 70 mg/dL or greater, or 100 mg/dL or greater, for patients with or without clinical ASCVD, respectively. A large proportion of patients with familial hypercholesterolemia belong to refractory hypercholesterolemia. This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of a single intravenous infusion of NGGT006 in patients with refractory Hypercholesterolemia diagnosed by gene testing for familial hypercholesterolemia. 3-9 subjects will be enrolled and divided into 3 groups according to the principle of dose escalation, respectively administered intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg). All subjects will undergo 52 weeks of treatment observation and further 260 weeks of long-term follow-up.

02

Conditions studied

  • Refractory Hypercholesterolemia
  • Familial Hypercholesterolemia

Keywords

  • Gene therapy
  • Low-density lipoprotein cholesterol
03

In context

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

This study's planned enrollment of 9 is below the median of 108 across 979 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Suzhou Municipal Hospital is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 ≤ age ≤ 55 years old;
  2. A patient with a clear diagnosis of hypercholesterolemia and confirmed by genetic testing to be familial hypercholesterolemia;
  3. AAV binding antibody titer ≤1:80 and AAV neutralizing antibody ≤1:5;
  4. 18≤ (body mass index)≤35;
  5. During the screening period, the subjects have received stable maximum tolerated dose of lipid-lowering drug treatment, but LDL-C was still ≥70mg/dL with clinical atherosclerotic cardiovascular disease; or LDL-C level was ≥ 100 mg/dL without clinical atherosclerotic cardiovascular disease: the highest tolerated dose refers to (the following must be met at the same time):

    ① Moderate to high doses of statins for ≥4 weeks, whether used alone or in combination with other lipid-lowering drugs; exceptions: subjects cannot tolerate statins; or subjects cannot receive statin treatment due to other reasons, such as low BMI, etc.;

    ② Ezetimibe ≥ 4 weeks;

    ③ Alirocumab 150mg Q2W or 300mg Q4W; evolocumab 140mg Q2W or 420mg Q4W; ≥8 weeks; And during the clinical trial process, any adjustment involving the type and dosage of lipid-lowering drugs must be approved by the researcher;

  6. Stable healthy diet for ≥12 weeks, and can adhere to a healthy diet throughout the entire clinical trial;
  7. Voluntarily sign the form and be willing to comply with the trial visit plan;
  8. Willing to maintain a similar amount and intensity of exercise during the study period as during the baseline period;
  9. Maintain good living habits, have no history of alcoholism or alcohol dependence (ICD-10 diagnosis is F10)
  10. No new or recurring cardiovascular events (myocardial infarction, cerebral infarction, etc.) within half a year;
  11. No stent implantation plan within three months;
  12. Female subjects have not had sexual intercourse for 14 days before administration, and their blood tests indicate that they are not pregnant;
  13. Subjects of childbearing age agree to use highly effective measures for at least 365 days from the time of NGGT006 administration.

Exclusion criteria

Exclusion Criteria:

  1. Secondary hyperlipidemia;
  2. Use of other drugs or nutritional products that may affect blood lipids (such as fibrates) within 6 weeks;
  3. Have received low-density lipoprotein apheresis (LDL apheresis) within the past 2 months;
  4. Large weight fluctuations (≥5kg) in the past 2 months;
  5. Positive for surface antigen, , (HIV),syphilis test or other infections (such as Epstein-Barr virus, Mycoplasma pneumoniae, tuberculosis virus, HPV, Chlamydia pneumoniae, respiratory syncytial virus, Adenovirus and coxsackievirus group B, etc.);
  6. abnormalities in liver function test: (ALT) >2 × (ULN) and/or aspartate aminotransferase (AST) >2 × ULN;
  7. RR at the baseline >160/100mmHg (one repeated measurement is allowed);
  8. Uncontrollable myocardial infarction or heart failure, and those planning surgery within one year; or new acute coronary syndrome in the past six months;
  9. Diabetes diagnosed within 3 months or with poor control ( >9%);
  10. Abnormal thyroid function, or those using thyroid hormone replacement therapy but poorly controlled (TSH within the normal range for \<12 weeks);
  11. Acute or chronic renal insufficiency;
  12. (Hb) \< 120g/L (male), Hb \< 110 (female);
  13. Abnormal counts or morphology;
  14. History or laboratory tests suggestive of thrombosis;
  15. Had to (e.g., epilepsy, severe schizophrenia, active peptic ulcer);
  16. Used systemic glucocorticoid treatment within 6 weeks before enrollment;
  17. less than 1 year;
  18. Suffering from malignant tumors such as liver cancer; liver fibrosis;
  19. Previous gene therapy treatment;
  20. to AAV preparations (for example trehalose) or cortisone or (sirolimus, rituximab, tacrolimus);
  21. Suffering from immunodeficiency disease
  22. Participation in any other clinical trial within 3 months;
  23. Breastfeeding females;
  24. Any other condition that may not be appropriate for the study in the opinion of the Investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    NGGT006

    3 doses of NGGT006 will be administered according to the principle of dose escalation

    Drug: NGGT006

Interventions

  • DrugNGGT006

    Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse events (AE) and serious adverse events (SAE)

    Incidence of AE and SAE, as assessed by physical examinations, clinical laboratory parameters and adverse event reporting

    Time frame: 52 weeks

  2. Absolute change and percent change in LDL-C

    Change in LDL-C concentration from baseline to week 52

    Time frame: 52 weeks

Secondary outcomes

  1. Absolute change and percent change in non-high density lipoprotein cholesterol

    Change in non-HDL-C from baseline to week 52

    Time frame: 52 weeks

  2. Absolute change and percent change in apolipoprotein B

    Change in ApoB from baseline to week 52

    Time frame: 52 weeks

  3. Absolute change and percent change in total cholesterol

    Change in TC from baseline to week 52

    Time frame: 52 weeks

  4. Absolute change and percent change in HDL-C

    Change in HDL-C from baseline to week 52

    Time frame: 52 weeks

  5. Absolute change and percent change in triglycerides

    Change in TG from baseline to week 52

    Time frame: 52 weeks

  6. Absolute change and percent change in very low-density lipoprotein cholesterol

    Change in VLDL from baseline to week 52

    Time frame: 52 weeks

  7. Absolute change and percent change in lipoprotein(a)

    Change in Lp(a) from baseline to week 52

    Time frame: 52 weeks

  8. Absolute change and percent change in apolipoprotein A-I

    Change in apo A-I from baseline to week 52

    Time frame: 52 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Mar 2025, 9 months later.

Of 46 phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 9 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 5, 2024
StartEst.
Jun 1, 2024
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 1, 2029
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06293729
Lead sponsor
Suzhou Municipal Hospital
Responsible party
Yan Chen (President of Suzhou Municipal Hospital, Suzhou Municipal Hospital) — Principal investigator
First posted
Mar 5, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Apr 17, 2024

Study contacts

Jun Zhang, MD
Contact
zhangjun0808@njmu.edu.cn
+86 0512-62363323
Yan Chen, PhD
Contact
Chenyandoc@163.com
+86 0512-62363323

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion